Check out the companies making headlines before the bell. Nvidia — Shares dipped 2%, adding to losses from Thursday when Nvidia closed down 3.5%. The decline comes after the AI chipmaker on Tuesday briefly topped Microsoft as the most valuable public company. Sarepta Therapeutics — The biopharma stock soared 37% after the U.S. Food and Drug Administration granted approval for Sarepta’s Elevidys gene therapy , which would treat patients with Duchenne muscular dystrophy. The therapy was traditionally approved for all patients four years or older who are able to walk, with accelerated approval given for those who cannot walk. Nike — The athletic clothing maker moved 1% higher following an upgrade at Oppenheimer to outperform from market perform. The firm also reinstated Nike as a top mega-cap pick, saying that the stock is poised to rebound gradually as the company refocuses on product innovation and brand-building. Asana — Shares popped more than 3% after the software firm announced a $150 million share buyback plan. The company expects its stock repurchase program to continue through June 30, 2025. Gilead Sciences — The pharmaceutical stock rose more than 2.6%, building on a rally of 8.5% from the previous session. On Thursday, Gilead announced that an HIV-prevention shot succeeded in a late-stage trial . LendingTree — Shares of the online lending marketplace were marginally lower after Bloomberg reported that hackers are now auctioning off stolen data from the site. LendingTree was the victim of a cyberattack against cloud computing firm Snowflake. Apple — Stock in the iPhone maker ticked up 1 following a price increase from Bernstein. Analyst Toni Sacconaghi asserted that the more bullish outlook is tied to his view that Apple can emerge as a leader of the artificial intelligence boom, “not a laggard.” Delta Air Lines — The stock rose 0.7% following news Thursday that the airliner announced a quarterly dividend of 15 cents a share, a 50% increase from previous levels. — CNBC’s Brian Evans, Michelle Fox, Jesse Pound and Sarah Min contributed reporting.
